Addex Therapeutics Ltd.

GENEVA, V8 · CIK 0001574232 · Biotech · Public

Orally available small molecule allosteric modulators for neurological disorders

addextherapeutics.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$14M
3 Form D · Apr 2023
42 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$5,935,118
Private capital raisedForm D · SEC$4,230,500
Private capital raisedForm D · SEC$3,733,334
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1874Factor Holdings LLC—$25K
1875TearSolutions, Inc.—$36M
1876Optimvia, LLC—$75K
1877Addex Therapeutics Ltd.—$14M
1878STEMBIOSYS, INC.—$3.4M
1879Prince Biotech, Inc.—$10M
1880TBC II LLC—$3.5M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 9 related persons
  • Timothy DyerDirector · Executive Officer
  • Raymond HillDirector
  • Mikhail KalinichevExecutive Officer
  • Vincent LawtonDirector
  • Robert LutjensExecutive Officer
  • Isaac MankeDirector
  • Roger MillsDirector · Executive Officer
  • Jake NunnDirector
  • Jean-Philippe RocherExecutive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.